<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sildenafil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sildenafil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sildenafil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11046" href="/d/html/11046.html" rel="external">see "Sildenafil: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13000" href="/d/html/13000.html" rel="external">see "Sildenafil: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220995"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Liqrev;</li>
<li>Revatio;</li>
<li>Viagra</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868230"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Sildenafil;</li>
<li>AG-Sildenafil;</li>
<li>APO-Sildenafil;</li>
<li>APO-Sildenafil R [DSC];</li>
<li>AURO-Sildenafil;</li>
<li>BIO-Sildenafil;</li>
<li>JAMP-Sildenafil;</li>
<li>JAMP-Sildenafil R;</li>
<li>M-Sildenafil;</li>
<li>Mar-Sildenafil;</li>
<li>MINT-Sildenafil;</li>
<li>NRA-Sildenafil;</li>
<li>PMS-Sildenafil R;</li>
<li>Priva-Sildenafil [DSC];</li>
<li>PRZ-Sildenafil;</li>
<li>Revatio;</li>
<li>RIVA-Sildenafil;</li>
<li>TEVA-Sildenafil;</li>
<li>TEVA-Sildenafil R;</li>
<li>Viagra</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F221028"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphodiesterase-5 Enzyme Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F221000"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Do <b>not</b> administer in patients taking nitrates (regularly or intermittently) due to risk for severe hypotension. If a patient taking sildenafil develops chest pain, delay therapy with a nitrate for 24 hours. For patients taking an alpha-blocking antihypertensive agent, use sildenafil with caution and consider a lower starting dose, as sildenafil can potentiate hypotensive effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khera.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khera.1'])">Ref</a></span>). Some experts recommend against routinely using these drugs together, particularly in patients with cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sauer.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77b945d9-a93d-48b1-8ab3-46e494efb128">Erectile dysfunction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erectile dysfunction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity. Reduce to 25 mg once daily if side effects occur. May increase to a maximum dose of 100 mg once daily if there is incomplete response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c52d7f2-7407-4a35-a79d-768591ea4db6">High-altitude pulmonary edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>High-altitude pulmonary edema (adjunctive therapy) (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i>
<b>Note:</b> May use as an adjunct to gradual ascent in high-risk individuals (eg, history of high-altitude pulmonary edema) who cannot take nifedipine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 50 mg every 8 hours starting the day of ascent; continue for 3 to 5 days after reaching maximal altitude (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1'])">Ref</a></span>); can extend for up to 7 days in individuals who ascend faster than recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i>
<b>Note:</b> Alternative agent when nifedipine is not available. Adjunctive to nonpharmacologic measures (eg, oxygen supplementation, portable hyperbaric chamber, gradual descent) or as monotherapy if nonpharmacologic measures are not possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 50 mg every 8 hours; continue until descent is complete, symptoms resolve, and oxygenation is normal for the altitude (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1','lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1','lexi-content-ref-31248818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b>
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, and cardiopulmonary comorbidities. Sildenafil is contraindicated in patients taking riociguat due to potentially severe hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg 3 times daily; some do not recommend titration to higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783'])">Ref</a></span>). However, in patients who fail to demonstrate or maintain an adequate clinical response, others consider slowly increasing the dose in 20 mg increments to a maximum dose of 80 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24937180','lexi-content-ref-16291984','lexi-content-ref-21546436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24937180','lexi-content-ref-16291984','lexi-content-ref-21546436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 10 mg 3 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fed0e48d-298d-453f-bda8-97189c608a2d">Raynaud phenomenon</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 mg once or twice daily; based on response and tolerability, may increase to 20 mg 3 times daily as needed; if lower doses are ineffective, may increase further to 40 mg 3 times daily if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wigley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wigley.1'])">Ref</a></span>); others have reported using 50 mg 2 to 3 times daily as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28281457','lexi-content-ref-16275885','lexi-content-ref-Wigley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28281457','lexi-content-ref-16275885','lexi-content-ref-Wigley.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion between oral sildenafil and IV sildenafil:</b> A 10 mg IV sildenafil dose is expected to provide similar effects as a 20 mg oral dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21219411','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21219411','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991396"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although only 13% of sildenafil is excreted in the urine, the AUC is approximately doubled in patients with CrCl &lt;30 mL/minute, most likely due to a decrease in hepatic function associated with uremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11879256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11879256'])">Ref</a></span>); use with caution when initiating therapy or with any increase in dose in these patients, including patients on renal replacement therapies. Additionally, although there are no specific dosage adjustments recommended for off-label indications (has not been studied), the same general dosing principles may apply for these indications in patients with altered kidney function or on renal replacement therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary arterial hypertension</i>: No dosage adjustment necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Erectile dysfunction:</i> Initial: 25 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11879256','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11879256','lexi-content-ref-Manu.1'])">Ref</a></span>). May cautiously increase dose based on tolerability and response. Maximum dose: 100 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): Oral, IV:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15200445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15200445'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary arterial hypertension:</i> No dosage adjustment necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Erectile dysfunction:</i> Initial: 25 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11176477','lexi-content-ref-11136178','lexi-content-ref-12175405','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11176477','lexi-content-ref-11136178','lexi-content-ref-12175405','lexi-content-ref-Manu.1'])">Ref</a></span>). May cautiously increase dose based on tolerability and response. Maximum dose: 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21072154','lexi-content-ref-12397048','lexi-content-ref-11522864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21072154','lexi-content-ref-12397048','lexi-content-ref-11522864'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Oral, IV: </b>Unlikely to be significantly dialyzable (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary arterial hypertension:</i> No dosage adjustment necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Erectile dysfunction:</i> Initial: 25 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11176477','lexi-content-ref-11587397','lexi-content-ref-11136178','lexi-content-ref-12175405','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11176477','lexi-content-ref-11587397','lexi-content-ref-11136178','lexi-content-ref-12175405','lexi-content-ref-Manu.1'])">Ref</a></span>). May cautiously increase dose based on tolerability and response. Maximum dose: 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15685517','lexi-content-ref-11522864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15685517','lexi-content-ref-11522864'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: <b>Oral, IV:</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary arterial hypertension:</i> There are no specific dosage adjustments recommended (has not been studied); however, dosage adjustment is likely unnecessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): <b>Oral, IV:</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary arterial hypertension:</i> There are no specific dosage adjustments recommended (has not been studied); however, dosage adjustment is likely unnecessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988593"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh classes A and B):</p>
<p style="text-indent:-2em;margin-left:4em;">Revatio, Liqrev: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Viagra: Starting dose of 25 mg should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C):</p>
<p style="text-indent:-2em;margin-left:4em;">Revatio, Liqrev: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Viagra: Starting dose of 25 mg should be considered.</p></div>
<div class="block doe drugH1Div" id="F221001"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Elderly &gt;65 years: Use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Erectile dysfunction (Viagra): Oral: Starting dose of 25 mg should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary arterial hypertension (Revatio, Liqrev): Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812553"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13000" href="/d/html/13000.html" rel="external">see "Sildenafil: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe included with the 10 mg/mL oral suspension only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe should be dispensed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Limited data available; duration of therapy not established; interpatient variability has been reported: Oral: Initial: 0.25 mg/kg/dose every 6 hours <b>or</b> 0.5 mg/kg/dose every 8 hours; titrate as needed; maximum reported dose range: 1 to 2 mg/kg/dose every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30396684','lexi-content-ref-21138617','lexi-content-ref-18950791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30396684','lexi-content-ref-21138617','lexi-content-ref-18950791'])">Ref</a></span>). <b>Note:</b> May consider lower initial doses (eg, 0.25 mg/kg/dose every 8 hours) in critically ill patients receiving concomitant vasoactive agents, especially infants &lt;4 months of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bednarz.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bednarz.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">≤20 kg: Oral: 10 mg three times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 to 45 kg: Oral: 20 mg three times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;45 kg: Oral: 20 mg three times daily; titrate as needed; maximum dose: 40 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec3bfef9-e81e-40c8-944e-4cc2f947f60c">Pulmonary hypertension, congenital heart disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension, congenital heart disease (postoperative):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (or nasogastric tube): Dosing regimens variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20206543','lexi-content-ref-34228973','lexi-content-ref-21720460','lexi-content-ref-20054528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20206543','lexi-content-ref-34228973','lexi-content-ref-21720460','lexi-content-ref-20054528'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral (or nasogastric tube): Initial: 0.5 mg/kg/dose increase in 0.5 mg/kg/dose increments every 4 to 6 hours up to a maximum dose of 2 mg/kg/dose as tolerated; upon discontinuation of mechanical ventilation, sildenafil therapy can be tapered over 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20206543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20206543'])">Ref</a></span>). <b>Note:</b> Use of preoperative sildenafil therapy for the prevention of pulmonary hypertension following congenital heart surgery has been reported and has produced variable efficacy results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34228973','lexi-content-ref-21720460','lexi-content-ref-21457152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34228973','lexi-content-ref-21720460','lexi-content-ref-21457152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Dosing regimens variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21069290','lexi-content-ref-26440237','lexi-content-ref-34143564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21069290','lexi-content-ref-26440237','lexi-content-ref-34143564'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &gt;60 days and Children: IV: Loading dose: Range: 0.04 to 0.35 mg/kg administered over 5 minutes, followed by a maintenance infusion: Reported range: 0.015 to 0.4 mg/kg/hour continued for 24 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21069290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21069290'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9726ff3-ada4-480f-af71-1c201a6cb5a0">Pulmonary hypertension, facilitation of inhaled nitric oxide wean</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who have <span style="text-decoration: underline">not</span> previously failed iNO wean):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤15 months: Oral (nasogastric): Single dose: 0.4 mg/kg/dose (range: 0.3 to 0.5 mg/kg/dose) given once 60 minutes prior to iNO discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16917115']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16917115'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729832"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Revatio: Children and Adolescents: Oral, IV: Mild, moderate, and severe impairment: No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F52729833"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Revatio: Children and Adolescents: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage recommendations in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55753786"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hearing loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sudden <b>auditory impairment </b>and <b>hearing loss </b>have occurred. Hearing changes are generally unilateral and may be accompanied by <b>tinnitus</b> and <b>dizziness</b>. A direct relationship between therapy and hearing loss has not been determined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21520123','lexi-content-ref-19507217','lexi-content-ref-28923561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21520123','lexi-content-ref-19507217','lexi-content-ref-28923561'])">Ref</a></span>). The potential hearing loss affects high frequencies and is reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19134242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19134242'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; several proposed mechanisms. May be related to elevated middle inner ear pressure which results from congestion of nasal erectile tissue. Intensification of effects of nitric oxide and/or activation of intracellular cyclic guanosine monophosphate (cGMP) may also contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20479381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20479381'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; most cases occur within 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19507217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19507217'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Modest decreases in blood pressure (ie, reductions of 7 to 10 mmHg in systolic and 7 mm Hg in diastolic pressure) may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18367027','lexi-content-ref-15533876','lexi-content-ref-22023666','lexi-content-ref-28923561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18367027','lexi-content-ref-15533876','lexi-content-ref-22023666','lexi-content-ref-28923561'])">Ref</a></span>). Blood pressure generally normalizes within 6 hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18367027','lexi-content-ref-10078541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18367027','lexi-content-ref-10078541'])">Ref</a></span>). Concurrent organic nitrate or guanylate cyclase stimulator therapy may potentiate the vasodilatory effects of sildenafil and produce severe <b>hypotension</b>; use is contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25657022','lexi-content-ref-16387566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25657022','lexi-content-ref-16387566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; inhibition of phosphodiesterase-5 (PDE-5) activity in the vascular smooth muscle results in vasodilation, which can lead to hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923561'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; decreases in blood pressure generally occur within 1 to 2 hours after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18367027','lexi-content-ref-10078541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18367027','lexi-content-ref-10078541'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that either potentiate the vasodilatory effects of sildenafil (eg, alpha-adrenergic antagonists) or increase sildenafil serum concentrations (eg, ritonavir) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900167'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antihypertensives</p>
<p style="text-indent:-2em;margin-left:6em;">• Left ventricular outflow obstruction (eg, aortic stenosis, idiopathic hypertrophic subaortic stenosis)</p>
<p style="text-indent:-2em;margin-left:6em;">• Resting hypotension (BP &lt;90/50 mm Hg)</p>
<p style="text-indent:-2em;margin-left:6em;">• Fluid depletion</p>
<p style="text-indent:-2em;margin-left:6em;">• Autonomic dysfunction</p>
<p style="text-indent:-2em;margin-left:6em;">• Hemodynamic instability</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Priapism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Painful <b>priapism</b> lasting &gt;4 hours in duration has been reported rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900167','lexi-content-ref-32622767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900167','lexi-content-ref-32622767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action; inhibition of phosphodiesterase-5 (PDE-5) activity, which leads to increased accumulation of cyclic guanosine monophosphate (cGMP) in response to release of nitric oxide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29667180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29667180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; has occurred shortly after orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900167'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Sildenafil overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900167'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that may cause priapism (eg, amitriptyline, nortriptyline, second-generation antipsychotics, trazodone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900167','lexi-content-ref-32622767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900167','lexi-content-ref-32622767'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Visual effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Visual disturbance</b> (including reversible cyanopsia [blue-tinged vision], photophobia, and blurred vision may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33809319','lexi-content-ref-32117027','lexi-content-ref-28923561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33809319','lexi-content-ref-32117027','lexi-content-ref-28923561'])">Ref</a></span>). Sudden <b>vision loss</b> in 1 or both eyes may occur and be a sign of nonarteritic <b>anterior ischemic optic neuropathy </b>(NAION); however, a direct relationship has not been determined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25295683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25295683'])">Ref</a></span>). Most visual disturbances are transient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826','lexi-content-ref-32117027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826','lexi-content-ref-32117027'])">Ref</a></span>). Cyanopsia, photophobia, and blurred vision typically resolve within 5 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33809319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33809319'])">Ref</a></span>). NAION complete resolution may be delayed (weeks to a year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27799745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27799745'])">Ref</a></span>). <b>Anterior uveitis</b>, <b>macular edema</b>, and <b>retinal artery occlusion</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36249994','lexi-content-ref-34761138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36249994','lexi-content-ref-34761138'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cyanopsia, photophobia, blurred vision: Dose-related; related to the pharmacologic action. May be a result of minor inhibition of phosphodiesterase-6 (PDE-6) which is expressed in rod and cone photoreceptor cells in the retina (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32117027','lexi-content-ref-27799745','lexi-content-ref-28923561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32117027','lexi-content-ref-27799745','lexi-content-ref-28923561'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• NAION: Not clearly established; may be due to hypoperfusion of ciliary arteries resulting from hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884471'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Cyanopsia, photophobia, blurred vision: Rapid; generally occur within 1 to 2 hours after ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33809319','lexi-content-ref-27799745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33809319','lexi-content-ref-27799745'])">Ref</a></span>). NAION: Varied; hours to months after ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27799745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27799745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For NAION:</p>
<p style="text-indent:-2em;margin-left:8em;">• Low cup-to-disc ratio ("crowded disc") (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (&gt;50 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coronary heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hyperlipidemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25358826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25358826'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F220962"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (9% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (9% to 12%), dyspepsia (3% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (16% to 49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3% to 13%), limb pain (7% to 15%), myalgia (2% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (2% to 11%; including vision color changes, blurred vision, and photophobia)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (2% to 3%; patients with pulmonary arterial hypertension secondary to connective tissue disorder: 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (&lt;2%), atrioventricular block (&lt;2%), cardiomyopathy (&lt;2%), chest pain (&lt;2%), ECG abnormality (&lt;2%), edema (&lt;2%), heart failure (&lt;2%), hypotension (&lt;2%), ischemic heart disease (&lt;2%), orthostatic hypotension (&lt;2%), palpitations (&lt;2%), peripheral edema (&lt;2%), shock (&lt;2%), syncope (&lt;2%), tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (&lt;2%), dermal ulcer (&lt;2%), diaphoresis (&lt;2%), exfoliative dermatitis (&lt;2%), pruritus (&lt;2%), skin photosensitivity (&lt;2%), skin rash (2% to 3%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (&lt;2%), hypernatremia (&lt;2%), hyperuricemia (&lt;2%), hypoglycemia (&lt;2%), increased thirst (&lt;2%), unstable diabetes (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;2%), colitis (&lt;2%), dysphagia (&lt;2%), esophagitis (&lt;2%), gastroenteritis (&lt;2%), gingivitis (&lt;2%), glossitis (&lt;2%), nausea (2% to 3%), rectal hemorrhage (&lt;2%), stomatitis (&lt;2%), vomiting (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia (&lt;2%), breast hypertrophy (&lt;2%), cystitis (&lt;2%), ejaculatory disorder (&lt;2%), genital edema (&lt;2%), nocturia (&lt;2%), urinary frequency (&lt;2%), urinary incontinence (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), leukopenia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (&lt;2%), hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (&lt;2%), absent reflexes (&lt;2%), asthenia (&lt;2%), ataxia (&lt;2%), cerebral thrombosis (&lt;2%), chills (&lt;2%), depression (&lt;2%), dizziness (2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (&lt;2%), falling (&lt;2%), hypertonia (&lt;2%), hypoesthesia (&lt;2%), migraine (&lt;2%), myasthenia (&lt;2%), neuralgia (&lt;2%), neuropathy (&lt;2%), pain (&lt;2%), tremor (&lt;2%), vertigo (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Sildenafil: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sildenafil)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sildenafil)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Erectile dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">511</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">607</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Erectile dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">607</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Erectile dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">607</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Erectile dysfunction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">734</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">725</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (&lt;2%), gout (&lt;2%), ostealgia (&lt;2%), osteoarthritis (&lt;2%), rupture of tendon (&lt;2%), synovitis (&lt;2%), tenosynovitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Anterior chamber eye hemorrhage (&lt;2%), cataract (&lt;2%), conjunctivitis (&lt;2%), dry eye syndrome (&lt;2%), eye pain (&lt;2%), mydriasis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment (&lt;2%), hearing loss (&lt;2%), otalgia (&lt;2%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (&lt;2%), bronchitis (&lt;2%), dyspnea (&lt;2%), increased bronchial secretions (&lt;2%), increased cough (&lt;2%), laryngitis (&lt;2%), nasal congestion (4% to 9%), pharyngitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Hayat 2007), hypertension, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma of skin (Loeb 2015), malignant melanoma (Li 2014; Loeb 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, priapism (Rezaee 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage, sickle cell crisis (vaso-occlusive crisis in patients with pulmonary hypertension associated with sickle cell disease) (Machado 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Pawar 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia (transient global), anxiety, cerebral hemorrhage, cerebrovascular hemorrhage, cranial nerve palsy (Lee 2021), psychosis (Shalbafan 2022), seizure (including recurrent seizures), subarachnoid hemorrhage (Adiya 2016), transient ischemic attacks (Morgan 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Anterior ischemic optic neuropathy (nonarteritic; NAION) (Campbell 2015), anterior uveitis (Regenold 2021), burning sensation of eyes, diplopia, eye redness, increased intraocular pressure, macular edema (Regenold 2021), retinal artery occlusion (Mahmoud 2022), retinal edema, retinal vascular disease, swelling of eye, vision loss, vitreous detachment, vitreous traction</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary hemorrhage</p></div>
<div class="block coi drugH1Div" id="F220974"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate); concomitant use of riociguat (a guanylate cyclase stimulator).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturers of protease inhibitors (atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir): Concurrent use with a protease inhibitor regimen when sildenafil is used for pulmonary artery hypertension.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Viagra: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION).</p>
<p style="text-indent:-2em;margin-left:4em;">Revatio: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION); concurrent use with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir); pulmonary hypertension secondary to sickle cell anemia; severe hepatic impairment; recent history of stroke or MI, or life-threatening arrhythmia; coronary artery disease causing unstable angina; severe hypotension (&lt;90/50 mm Hg) at initiation.</p></div>
<div class="block war drugH1Div" id="F220959"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Caution patients that concurrent use of alcohol, particularly in larger quantities, may increase the risk for orthostatic hypotension, dizziness, tachycardia, and headache. Recommend limiting any alcohol use to smaller quantities and refraining from such combined use as possible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders; safety has not been established. <i>In vitro</i> studies have suggested a decreased effect on platelet aggregation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypotension (&lt;90/50 mm Hg); uncontrolled hypertension (&gt;170/110 mm Hg); life-threatening arrhythmias, stroke or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina; safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). Patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. There is a degree of cardiac risk associated with sexual activity; therefore, health care providers should consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions predisposing to priapism: Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia). All patients should be instructed to seek immediate medical attention if erection persists &gt;4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary arterial hypertension: Sudden cessation of sildenafil monotherapy could result in an exacerbation of pulmonary arterial hypertension (PAH). Efficacy in adult patients determined through short-term (12 to 16 week) studies; safety of longer-term use is unclear. A long-term use trial in pediatric patients showed increased mortality in the higher dose groups (20 to 80 mg [depending upon weight] 3 times per day) after 2 years of use, which was related to disease progression (Barst 2012; Barst 2014; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary veno-occlusive disease: Use in patients with pulmonary veno-occlusive disease (PVOD) is not recommended (has not been studied); if pulmonary edema occurs when treating PAH, consider the possibility of PVOD.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell anemia: Treatment of pulmonary hypertension with sildenafil in this patient population may lead to more hospitalizations for management of vaso-occlusive crises. The effectiveness and safety of sildenafil have not been established in pulmonary hypertension secondary to sickle cell disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nitrates: Use of sildenafil is contraindicated in patients currently taking nitrate preparations. However, when nitrate administration becomes medically necessary, American College of Cardiology/American Heart Association guidelines support administration of nitrates only if 24 hours have elapsed after use of sildenafil (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]); may need to wait longer than 24 hours in patients with renal or hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; dose adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suspension: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes.</p></div>
<div class="block foc drugH1Div" id="F220969"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revatio: 10 mg/12.5 mL (12.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/12.5 mL (12.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Liqrev: 10 mg/mL (122 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revatio: 10 mg/mL (112 mL) [contains sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (112 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revatio: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viagra: 25 mg, 50 mg, 100 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F220955"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F220977"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Revatio Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/12.5 mL (per mL): $24.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sildenafil Citrate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/12.5 mL (per mL): $17.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Liqrev Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $18.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Revatio Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $109.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Sildenafil Citrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $1.07 - $87.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Revatio Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $70.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sildenafil Citrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $19.00 - $22.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.11 - $66.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.11 - $66.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.11 - $66.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Viagra Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $99.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $99.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $99.92</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868231"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revatio: 10 mg/12.5 mL (12.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revatio: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viagra: 25 mg, 50 mg, 100 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 25 mg, 50 mg, 100 mg</p></div>
<div class="block adm drugH1Div" id="F220971"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Revatio, Liqrev: Administer doses with or without food. Shake oral suspension well for ≥10 seconds before administering each dose; do not mix with any other medication or additional flavoring agent. Administer with an accurate measuring device (eg, calibrated oral syringe).</p>
<p style="text-indent:-2em;margin-left:4em;">Viagra: Administer with or without food 30 minutes to 4 hours before sexual activity</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Revatio: Administer as an IV bolus.</p></div>
<div class="block admp drugH1Div" id="F52613852"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Revatio: <b>Note:</b> Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe included with the 10 mg/mL oral suspension only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe should be dispensed.</p>
<p style="text-indent:-2em;margin-left:4em;">Administer doses at least 4 to 6 hours apart; may be administered without regard to meals; shake oral suspension well prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Revatio:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous</i>
<i> IV infusion:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: Usually administered over 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35624452','lexi-content-ref-31740991','lexi-content-ref-19836028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35624452','lexi-content-ref-31740991','lexi-content-ref-19836028'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous IV infusion: Administer as a continuous IV infusion with the use of an infusion pump.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent IV infusions:</i> Infusion time variable; infuse over 1 hour, longer infusion times are commonly used to minimize risk of hypotension; reported infusion times range: 15 minutes to 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27340796','lexi-content-ref-27877095','lexi-content-ref-34052232','lexi-content-ref-28645441','lexi-content-ref-34143564','lexi-content-ref-23413163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27340796','lexi-content-ref-27877095','lexi-content-ref-34052232','lexi-content-ref-28645441','lexi-content-ref-34143564','lexi-content-ref-23413163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infant, Children, and Adolescents: In clinical trials, loading dose was administered as a bolus over 5 minutes, followed by a continuous IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21069290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21069290'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F220970"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Erectile dysfunction:</b> Viagra: Treatment of erectile dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b> Treatment of pulmonary arterial hypertension (WHO group I) in adults to improve exercise ability and delay clinical worsening (Revatio, Liqrev); treatment of pulmonary arterial hypertension (WHO group I) in pediatric patients 1 to 17 years of age to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise (Revatio).</p></div>
<div class="block off-label drugH1Div" id="F25744905"><span class="drugH1">Use: Off-Label: Adult</span><p>High-altitude pulmonary edema; Raynaud phenomenon</p></div>
<div class="block mst drugH1Div" id="F221036"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revatio may be confused with ReVia, Revonto</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sildenafil may be confused with silodosin, tadalafil, vardenafil</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viagra may be confused with Allegra, Vaniqa</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F221022"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F220964"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective).  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: May decrease the serum concentration of Sildenafil. Sildenafil may increase the serum concentration of Bosentan. Management: When sildenafil is used for treatment of pulmonary arterial hypertension (PAH), coadministration of sildenafil and bosentan is not recommended. Otherwise, monitor for reduced sildenafil efficacy if combined with bosentan.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Sildenafil. Management: Use of cobicistat and sildenafil for the treatment of PAH is contraindicated. If using sildenafil for the treatment of erectile dysfunction, limit the sildenafil dose to 25 mg and do not use more frequently than every 48 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary arterial hypertension (PAH) should be avoided with strong CYP3A4 inhibitors. When used for erectile dysfunction, consider using a lower starting dose of 25 mg and monitor patients for sildenafil toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Sildenafil. Management: For pulmonary arterial hypertension, no dose adjustment required. For erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin. Monitor patients for sildenafil toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Sildenafil. Management: For pulmonary arterial hypertension, no dose adjustment required. For erectile dysfunction, use a lower starting dose of 25 mg in patients who are also taking lenacapavir. Monitor patients for sildenafil toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Use of protease inhibitors and sildenafil for the treatment of PAH is contraindicated. If using sildenafil for the treatment of erectile dysfunction, limit the sildenafil dose to 25 mg and do not use more frequently than every 48 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vericiguat: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F220991"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase serum levels/toxicity of orally administered sildenafil. Management: Monitor for increased effects/toxicity with concomitant oral use.</p></div>
<div class="block pri drugH1Div" id="F220978"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sildenafil was shown to cross the placenta in an ex vivo placenta perfusion study (Russo 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Because sildenafil causes vasodilation in the uterus, it is currently under study for various obstetric uses (Dunn 2016; Dunn 2017; Groom 2019; Maged 2018; Maher 2019; Pels 2017; Sharp 2018). However, due to adverse events in the newborn observed using preliminary data from a study evaluating sildenafil for fetal growth restriction, use of sildenafil in pregnant women outside of a controlled clinical study is not currently recommended (Groom 2018; Levin 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in pregnant women is limited (Cartago 2014; Hsu 2011; Lim 2019; Wollein 2016). Untreated PAH in pregnancy increases the risk for heart failure, stroke, preterm delivery, and maternal/fetal death. Women with PAH are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>
<div class="block brc drugH1Div" id="F16571140"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The excretion of sildenafil and desmethylsildenafil in breast milk was described in a case report following maternal use for the treatment of PAH (Wollein 2016).</p></div>
<div class="block mop drugH1Div" id="F14971852"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor blood pressure and pulse when used concurrently with medications that lower blood pressure; monitor for pulmonary edema</p></div>
<div class="block pha drugH1Div" id="F220958"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Erectile dysfunction: Does not directly cause penile erections but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary arterial hypertension (PAH): Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.</p></div>
<div class="block phk drugH1Div" id="F220973"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Erectile dysfunction: ~60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Decrease blood pressure: Oral: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Erectile dysfunction: 2 to 4 hours; Decrease blood pressure: &lt;8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; slower with a high-fat meal; tablet and suspension are bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into tissues.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub> total:</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates: 19.8 to 22.4 L (Mukherjee 2009; Rhee 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>dss</sub>: Adults: 105 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates: Sildenafil: 93.9% ± 2.5%; N-desmethyl metabolite: 92% ± 3% (Mukherjee 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Sildenafil and N-desmethyl metabolite: ~96%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 (major) and CYP2C9 (minor route); major metabolite (UK-103320 or desmethylsildenafil) is formed via N-desmethylation pathway and has 50% of the potency of sildenafil.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Mean: 41%; range: 25% to 63%; may be higher in patients with PAH compared to healthy volunteers; <b>Note:</b> A 10 mg dose of the injection is predicted to have an effect equal to a 20 mg oral dose taking into consideration the parent drug and active metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Sildenafil: Terminal:</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates (Mukherjee 2009):</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 1 day: 55.9 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA 7 days: 47.7 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Active N-desmethyl metabolite: Terminal:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: 11.9 hours (Mukherjee 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: Fasting: 30 to 120 minutes (median 60 minutes); delayed by 60 minutes with a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~80%, as metabolites); urine (~13%).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Decreased in patients with hepatic cirrhosis or severe renal impairment; clearance may be lower in patients with PAH compared to normal volunteers. Sildenafil clearance in newborns is significantly decreased compared to adults, but approaches adult (allometrically scaled) values by the first week of life (Mukherjee 2009). Clearance of N-desmethyl active metabolite is decreased in patients with severe renal impairment.</p></div>
<div class="block phksp drugH1Div" id="F51159892"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Severe renal impairment is associated with increased plasma levels.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Hepatic impairment is associated with increased plasma levels.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Age 65 years or older is associated with increased plasma levels.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F220980"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bluvisa | Erecta | Eregra | Fallah | Maestro | Sife | Silafil | Sildomax | Siler | Tournes | Viagra | Viatuff | Vigalife | Vilna | Wafi | Zed</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">4 x 4 | Almaximo | Anaus | Bifort | Cagno | Egomax | Erectol | Expit | Falic | File | Firmel | Gimonte Sildenafil | Hepil | Incresil | Juvigor | Labsamax | Lumix | Magnus | Magnus Flash | Maxdosa | Maxdosa hap | Nexofil | Nitro | Openvas | Oxivital | Paramen | Pluspen | Segurex | Sildefil | Sildenafil | Sildenafil Hlb | Sildenafil Ilab | Sildenafil sandoz | Sildenafil Vannier | Super O | Tecnomax | Verum | Viagra | Vimax | Vimax flash | Virilon | Viripotens | Vitarfil | Vorst</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cilafil | Granpidam | Pulmolan | Pulmopresil | Revatio | Sildenafil | Sildenafil 1 A Pharma | Sildenafil A Med | Sildenafil Actavis | Sildenafil Genericon | Sildenafil pfizer | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil stada | Sildenafil teva | Sildenafil viatris | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo sildenafil | Apo sildenafil pht | Avigra | Cm sildenafil | Ernafil | Kopigra dr | Lisan | Mevia | Noumed sildenafil | Pharmacor sildenafil | Revatio | Silaran | Sildaccord | Sildanil | Sildenafil Actavis | Sildenafil an | Sildenafil an pht | Sildenafil aspen | Sildenafil drla | Sildenafil drx | Sildenafil gh | Sildenafil hx | Sildenafil lupin | Sildenafil medis | Sildenafil pfizer | Sildenafil ranbaxy | Sildenafil rbx | Sildenafil sandoz | Sildenafil watson | Sildocor | Silerec | Tw sildenafil | Vasafil | Vedafil | Viagra | Wafesil | Zelnafil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adegra | Aggra | Danafil | Edegra | Enegra | Enigma | Enjofil | Fulfeel | Immense | Niagra | Novagra | Panagra | SB sild | Silagra | Silfil | V gra | Viamax | Vigorex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Revatio | Sildenafil apotex | Sildenafil eg | Sildenafil mylan | Sildenafil sandoz | Sildenafil teva | Sildenon | Verventi | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Asmoforce | Erekta | Giagra | Kamagra | Plaevz | Powergra | Rigide | Sidegra | Viagra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Ecriten | Eroton | Revatio | Silden | Sildenafil | Sildenafil Medana | Sildenafil ratiopharm | Sildenafil stada | Silegria | Sinegra | Taxier | Viagra | Vigrande | Vizarsin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ah zul | Blupill | Citrato de sildenafila | Dejavu | Escitan | Prilo | Revatio | Sildara | Sollevare | Suvvia | Tantrix | Vasifil | Viagra | Viasil | Videnfil | Virineo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Revatio | Sildenafil Actavis | Sildenafil axapharm | Sildenafil helvepharm | Sildenafil mepha | Sildenafil nobel | Sildenafil PAH Mepha | Sildenafil pah mylan | Sildenafil pah spirig hc | Sildenafil pfizer | Sildenafil sandoz | Sildenafil spirig hc | Sildenax | Viagra</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Asmoforce | Erector | Erefil | Giagra | Kifaru | Plaevz | Plasir | Rigide | Sidegra | Silagra | Silnafil | Viagra | Viatec | Vigofeel | Vigorex | Virectil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alfin | Dirtop | Disilden | Erosfil | Esantop | Exifol | Falom | Helpin | Hetagra | Lifter | Novalif | Plusefec | Ripol | Seler | Siafil | Viagra | Vigorex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jin ge | Viagra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Afrosyn | Aleos | Biflace | Brios komplet man | Chaz | Ciaplen | Diserec | Disfureck | Dyna sex | Efeza | Ejertol | Elebra | Eleve | Erassin | Erecfor | Erefil | Erilin | Eroxim | Ex max | Fulerec | Gelpin | Gelpin fast | Hormotone | Lucidril | Maxeril | Montriex | Parolex | Placidium | Placidum | Plenifil | R sione | Renafil | Rociblue | Sentilux | Sildafil | Sildelife | Sildenafil | Sildenafil citrato | Sildenafil mk | Sildenafilo | Sildufi | Sindevalfir | Sinfer | Sinota | Tranky | Varofil | Viagra | Viagra odt | Vifortil | Vigradina | Vimax | Vintix | Vyasil forte | Vygrand</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Ero plus</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amfidor | Balcoga | Ecriten | Granpidam | Grasil | Modrasil | Mysildecard | Olvion | Revatio | Silaxa | Sildenafil accord | Sildenafil Actavis | Sildenafil apotex | Sildenafil Aurovitas | Sildenafil Medana | Sildenafil medreg | Sildenafil mylan | Sildenafil pfizer | Sildenafil sandoz | Sildenafil teva | Silfeldrem | Viagra | Vigrande | Vizarsin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arifil | Duraviril | Ereq | Granpidam | Mysildecard | Revatio | Sildaristo | Sildegra | Sildehexal | Sildenafil | Sildenafil 1a pharma | Sildenafil Actavis | Sildenafil Aliud | Sildenafil aristo pah | Sildenafil aurobindo | Sildenafil axunio | Sildenafil Basics | Sildenafil beta | Sildenafil biomo | Sildenafil FairFarma | Sildenafil Hennig | Sildenafil heumann | Sildenafil holsten | Sildenafil Hormosan | Sildenafil macleods | Sildenafil Neuraxpharm | Sildenafil pfizer | Sildenafil puren pah | Sildenafil ratiopharm | Sildenafil stada | Sildenafil sun | Sildenafil Uropharm | Sildenafil zentiva | Silnerton | Sinegra | Valedonis | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Vizarsin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Erec-F | Eroxim | Gerosex | Jumper | Levapen | Patrex | Pronac | Revive | Silden | Sildenafil | Sildenafil citrato | Sildenafil if | Spetrum | Veradur | Vergadur | Viafran | Viagra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Almaximo | Caverta | Equis x | Equis x da | Erecstar | Erectron | Erekctil | Erotil | Five films | Fogo | Funcional | Max | Medovigor | Potencil | Rezum | Ripol | Sildenafil | Sildenafil mk | Sildenafilo | Sutra | Trepol | Venux | Verec | Viagra | Vigorex | Vigoril | Xex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Granpidam | Mysildecard | Olvion | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil Medana | Sildenafil pfizer | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil teva | Silungo | Viagra | Vigrande | Vizarsin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Brilliant | Ectagor | Erec | Erecton | Ezequel | Kemagra | Napifit | Oragawell | Orgodenafil | Respatio | Satenafil | Silanil | Sildatrona | Sildava | Silden | Sildenafil mylan | Sildinax | Silvagra | Silvigo | Spika | Stimu max | V gone | Veora | Vetoyagra | Viagra | Viavag | Vigadol | Vigor | Vigoran | Vigorex | Virecta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Dragul | Fexion | Galotam | Granpidam | Mysildecard | Oximum | Psiliber | Revatio | Sildenafilo Actavis | Sildenafilo Almus | Sildenafilo Apotex | Sildenafilo aristo | Sildenafilo bluefish | Sildenafilo cinfa | Sildenafilo cinfamed | Sildenafilo combix | Sildenafilo dr. reddys | Sildenafilo Kern Pharma | Sildenafilo krka | Sildenafilo Mylan | Sildenafilo Normon | Sildenafilo pensa | Sildenafilo Ratiopharm | Sildenafilo Sandoz | Sildenafilo Stada | Sildenafilo tarbis | Sildenafilo TecniGen | Sildenafilo teva | Sildenafilo zentiva | Viagra | Vizarsin | Zuandol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Akigra | Kamagra | Seedios | Seldipro | Sildenafil | Temptcure | Viagra | Vigeranafil | Virecta | Zimagra</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Granpidam | Mysildecard | Orisild | Revastad | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil aspen | Sildenafil orifarm | Sildenafil orion | Sildenafil pfizer | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil stada | Sildenafil teva | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cetinor | Granpidam | Mysildecard | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil almus | Sildenafil arrow | Sildenafil biogaran | Sildenafil cristers | Sildenafil eg | Sildenafil mylan | Sildenafil pfizer | Sildenafil ranbaxy | Sildenafil sandoz | Sildenafil teva | Sildenafil zentiva | Sildenafil zydus | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aronix | Eropid | Granpidam | Liberize | Mysildecard | Revatio | Sildenafil | Sildenafil bristol lab | Sildenafil hameln | Sildenafil teva | Viagra | Viagra connect | Vizarsin | Zamantos</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Blugral | Bluozi | Dialex | Licosil | Olvion | Revatio | Sildenafil Actavis | Sildenafil heremco | Sildenafil liconsa | Sildenafil mylan | Sildenafil pfizer | Sildenafil teva | Sildenafil/bausch | Sildenafil/gerolymatos | Sildenafil/lyofin | Sildenafil/Sandoz | Sildenafil/vianex | Strondem | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Elonza | Erecor 100 | Erecto | Ericfil | Ernafil | Finegra | Hippigra | Maxigra | Pms sildenafil R | Powergra | Revatio | Silagra | Silden | Sildenafil stada | Silvie | Sinafil | Sliting | Tigerfil | Veligo | Viagra | Vilakra | Willmon | Zygra</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dinamico | Granpidam | Revatio | Sildenafil pliva | Tornetis | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ecriten | Erasilton | Revatio | Sildegra | Sildenafil mylan | Sildenafil pfizer | Sildenafil Pharmacenter | Sildenafil rivopharm | Sildenafil sandoz | Sildenafil teva | Silderec | Vegamac | Viagra | Viandros | Vigrande | Vizarsin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Caprenafil | Emposil | Ericfil | Legra | Revatio | Sanbenafil | Sildenafil | Topgra | Viagra | Viajoy | Vimax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Blugral | Granpidam | Mysildecard | Revatio | Sidena | Silcarfil | Sildenafil | Viagra | Viagra connect | Vizarsin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tarim | Viagra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">1-2-3 | 11PM | Adams delite | Alsigra | Androz | Assurans | Caverta | Dasutra x | Double force | Dr.x | Edegra | Edysafe | Enthusia | Erec | Eriacta | Erix | Eunice | Exygra | Fildena | Fire | Hernafil | Instarise | Intagra | Integra | Joshila | Juan | Kamagra | Lupigra | Lyga | Macsutra | Manegra | Manforce | Maxbull | Niagra | Nyte | Omnigra | Pah | Pefomax | Penegra | Piyagra | Playgard | Primiwal s | Progra | Pulmoday | Rezum | Seleg | Seregra | Shefill | Sil xt | Silagra | Sildegat | Suhagra | Tonite | Ulti-mate | Ultimate | Unigra | Uplift | Vasosure | Vigora | Vigreks | Viraha | Virecta | Vistagra | Vogira | Volo | Wavegra | Wingora | Xplod-s | Zeagra | Zenegra | Zestogra</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Samagra</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Azurvig | Balcoga | Blugral | Granpidam | Mendie | Mysildecard | Prelud | Rabestrom | Revatio | Sildenafil | Sildenafil abc | Sildenafil accord | Sildenafil Actavis | Sildenafil almus | Sildenafil aristo | Sildenafil aurobindo | Sildenafil caber | Sildenafil doc | Sildenafil dr. reddy's | Sildenafil eg | Sildenafil germed | Sildenafil macleods | Sildenafil ranbaxy | Sildenafil sandoz | Sildenafil tecnigen | Sildenafil zentiva | Siler | Viagra | Viagra farmed | Vizarsin | Zakfil</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Adenafil | Aphrodil | Bluvisa | Klick | Viagra | Vigain | Vigro | Vonta | Zed | Zoltan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Revatio | Sildenafil | Sildenafil towa | Sildenafil vi | Viagra</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Antigara | Aphrodis | Astagra | Celitra | Cenforce | Comit | Cosagra | Degra | Enogra | Evagra | Evoke | Filaven | Giagra | Gomore | Hot | Kamagra | Kifaru | Manforce | Mtm | Mygra | Negax | Nelgra | Njoi | Plamore | Powergra | Seldipro | Seregra | Sforce | Siloflam | Synogra | Tiagra | Vega | Vegon | Viagra | Viatuff | Vigorex | Vionex | Zedgra | Zegra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Agnafil | Allat's | Balgria | Bamirac | Bizela | Bogra | Candegra | Cengla | Confidence | Daewoongbio sildenafil | Denargra | Edforce | Erenafil | For mr. | Forte v | Fortera | Freegra | Freestin | Freeya | H U | Happigra | Hecate | Heragra | Maxigra | Maxigra odt | Navigra | Newbigra | Nurigra | Obaram | Padenafil | Pahtension | Palpal | Pristine | Progra | Revatio | Rufian | Sengla | Sildenafil | Silvie | Syrius | Thor s | Unigra | Valtax | Varofil | Viagra | Viaris | Vistra | Viya | Zygra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Maestro | Revatio | Viagra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aphrodil | Degra | Erector | Please | Segurex | Seldan | Sildenafil Arrow Lab | Tournes | Vega Plus | Viadis | Viagra | Vigoram | Vigro | Virecta | Vonta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ecriten | Gladix | Granpidam | Mysildecard | Olvion | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil Medana | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil Teva Pharma | Sildenafil torrent | Silungo | Taxier | Viagra | Vigrande | Vizarsin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sildehexal | Sildenafil apotex | Sildenafil eg | Sildenafil ratiopharm | Sildenon | Verventi | Viagra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ecriten | Granpidam | Mysildecard | Olvion | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil teva | Silungo | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Erector | Kamagra | Revatio | Sildenafil | Viagra | Viarect | Vibrex | Vigorex | Vimax | Zoltan</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Vizarsin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Actiraam | Apodefil | Bisglow | Blitsons | Bullenza | Delectat orm | Dionixol | Edegra | Figral | Forzandros | G4 | Go | Lerk | M force | Maxifort Zimax | Mazzogran | Ormokron | Orthiox | Osidea gl | Osideagl | Patrex | Revathio | Revatio | Rindec quim | Sildenafil | Sildenafil accord | Sildenafil lilly | Sindebax | Tomirat | Trectyl | Vegron | Viagra | Viagra odt | Viather by corne | Vitanafil | Voguel | Ysus</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Androz | Avogra | Axcel sildenafil | Caverta | Edyfil | Elonza | Giagra | Iqnyde | Maxefil | Revatio | Sildegra | Viagra</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Agedol | Bleorga | Exxgraa | Garyagra | Global young sildenafil citrate | Homograe | Homotex | Hygra | Intracell's sildenafil citrate | Jozogra | Jubigra | Kifaru | Koyogra | Lemdafil | Liricon sildenafil | Manimax | Njoi | Nubbaxx | Oliga | Penegra | Saodafil | Sd sildenafil | Shree manup | Sigra | Silamac | Sildenafil | Sildigra | Simbagra | Sofigor | Stayon | Sun filup | Taiga | Tiveka | Topigra | Veez | Vegaasia | Vennat | Vigabase | Vigafit | Welgamax | Wingora | Wooga | Zoga</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Granpidam | Mysildecard | Revatio | Sildenafil | Sildenafil accord | Sildenafil Actavis | Sildenafil apotex | Sildenafil mylan | Sildenafil sandoz | Sildenafil xiromed | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Granpidam | Mysildecard | Orisild | Revatio | Sildenafil Actavis | Viagra</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Avigra | Noumed sildenafil | Revatio | Silagra | Silvasta | Vedafil | Viagra</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Agrafil | Akabar | Alclimax | Atizalo max | Blue up | Caverta | Circulass | Circulass rapid | Ejertol | Elevamax | Erectol Plus | Erevit | Free lover | Helpin | Lyons | Pasuma nf | Penon | Plenylife | Porte | Pramil | Pramil forte | Rhocamass | Ripol | Sextreme | Sildamek | Sildecin | Sildemax | Silden up | Sildenafil | Sildenafilo | Sildenal | Sildenazinn | Silderec | Sildex | Sildexcel | Silfil | Sitrepa | Sutra | Venux | Viagra | Viagra odt | Vialza | Vimax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ambigra | Andros | Erefil | Kohagra | Penegra | Plefil | Pronafil | Sildenafil | Sildora | Spiagra | Tigerfil | Viagra | Virtus | Vivax | Zenera | Zilden</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Actigra | Ecriten | Falsigra | Granpidam | Lekap | Maxigra max | Maxon | Maxon active | Maxon forte | Princex | Remidia | Revatio | Silandyl | Silcontrol | Silden | Sildenafil accord | Sildenafil Actavis | Sildenafil apotex | Sildenafil Aurovitas | Sildenafil axxon | Sildenafil bluefish | Sildenafil espefa | Sildenafil genoptim | Sildenafil Medana | Sildenafil medical valley | Sildenafil medreg | Sildenafil ranbaxy | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil symphar | Sildenafil teva | Sildenafil vitama | Sildenafil zentiva | Sildenafilum farmacom | Silungo | Valinger | Valinger forte | Viagra | Viagra connect max | Vigrande | Vizarsin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Revatio | Sildenafil | Viagra</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amfidor | Blugral | Erepry | Granpidam | Mysildecard | Revatio | Sildenafil | Sildenafil Actavis | Sildenafil alter | Sildenafil aurobindo | Sildenafil Aurovitas | Sildenafil azevedos | Sildenafil bluefish | Sildenafil Ciclum | Sildenafil farmoz | Sildenafil gp | Sildenafil Jaba | Sildenafil krka | Sildenafil labesfal | Sildenafil mylan | Sildenafil odipe | Sildenafil osir | Sildenafil Pentafarma | Sildenafil pfizer | Sildenafil pharmakern | Sildenafil pinopharma | Sildenafil ratiopharm | Sildenafil reconir | Sildenafil sandoz | Sildenafil Sidefarma | Sildenafil siltop | Sildenafil tecnigen | Sildenafil teva | Sildenafil toLife | Sildenafil wynn | Sildenafil zentiva | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Almaximo | Dinagram | Dualsex | Levantol | Magnus | Maxdosa | Placer x | Pramil | Pramil forte | Priloc | Procops | Rigix | Rindemax | Ripol | Sacac | Sildenafil citrato | Sildenafil genfar | Sildenafil incomex | Sildenafil medicine | Sildenafil millet | Sildenafil vent 3 | Sobrium | Tenon | Viagra | Vimax | Viril | Zilfic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aladin | Aphrodil | Caverta | Degra | Silden | Viagra | Zed-100 | Zed-50</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Granpidam | Mysildecard | Olvion | Revatio | Sildenafil bioeel | Sildenafil medreg | Sildenafil teva | Taxier | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Caverta | Dynamico | Erexesil | Kamastil | Maxigra | Olmax Strong | Reejump | Revatio | Sealex sildenafil | Silafil | Silden | Sildenafil | Sildenafil cardio | Sildenafil Effax | Sildenafil fpo | Sildenafil zentiva | Taxier | Tornetis | Viagra | Viasan lf | Viatile | Vildegra | Vizarsin | Vizarsin q tab</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aladin | Aphrodil | Apo sildenafil | Essera | Fallah | Pms sildenafil R | Revatio | Silafil | Turbo | Viagra | Virecta | Virectil | Wafi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Granpidam | Idilico | Mysildecard | Orisild | Revastad | Revatio | Sildenafil | Sildenafil 1a farma | Sildenafil accord | Sildenafil Actavis | Sildenafil aspen | Sildenafil medical valley | Sildenafil orifarm | Sildenafil orion | Sildenafil pfizer | Sildenafil sandoz | Sildenafil stada | Sildenafil teva | Sildorin | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">A sildenafil | Androz | Ernafil | Remenafil | Sildegra | Sildenafil stada | Viagra | Vivic</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Balcoga | Belfil | Mysildecard | Sildenafil stada | Sildenafil teva | Tornetis | Viagra | Vizarsin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amfidor | Balcoga | Ecriten | Eremed | Grasil | Modrasil | Olvion | Revatio | Silandyl | Sildenafil Actavis | Sildenafil Medana | Sildenafil medreg | Sildenafil mylan | Sildenafil Netpharma | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil saneca | Sildenafil teva | Silfeldrem | Viagra | Vigrande | Viner | Vizarsin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Comit | Power play | Power shooter | Vegon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Elonza | Revatio | Silatio | Sildenafil | Sinafil | Tonafil | Viagra</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adenafil | Antar | As one | Erecta | Revatio | Sildenafil Actavis | Viadis | Viagra | Viatec | Zoltan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Combo | Degra | Egira | Newagra | Pularter | Retomin | Revatio | Sildegra | Silfect | Silmed | Sinegra | Viagra | Viamed | Vigaroo | Vigrande</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Allnight | Apo sildenafil | Ding hao | Erecter | Fullpower | Ganstrong | Holi up | Jubilant sildenafil | Okpower | Onlee | Penegra | Revatio | Shilifil | Sidneagra | Sife | Silafi | Sildegra | Silden | Sildenafil | Sinaf | Sliting | Slivien | Songra | Uppu | Viagra | Wellnitin | Yto</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alti met | Conegra | Conegra classic | Erasmo | Erectyl | Ero life | Erosil | Eroton | Filap | Genagra | Intagra ic | Kamafeel | Konegra | Lovigra | Maxigra | Moginin | No-lag | Novagra | Novagra euro | Novigra | Penigra | Penimax | Penimex | Potentiale | Revatio | Silada | Silagra | Sildenafil | Sildenafil ananta | Sildex | Sinegra | Superviga | Tegrum | Vectra | Viagra | Viagra odt | Viasil | Vigramax | Vizarsin | Vizarsin q tab</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Astagra | Erecto | Evoke | Giagra 100 | Kamagra | Kamagra 100 | Mardagra | Penegra | Satisfil | Sife | Sildenafil accord | Silmelt | Viagra | Virecta | Vivax | Zeegra | Zoy</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Exitomin | Libiden | Maxfil | Novopramil | Opcion | Plenovit | Segurex | Sildenafil | Sildenafilo | Viagra | Vimax | Vimax odt</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adegra | Dugasek | Durofil light | Duroval | Erbrix | Itaka | Kamagra | Sildenafil | Sildenafil citrato | Sildenafil GC | Sildenafilo | Sildex | Stigmax | Viagra | Viasek | Vigrasol | Vioses | Viridil | Zost</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Adagrin | Azodra | Daygra | Desilmax | Erecfil | Happygra | Maxxsat | Medovigor | Meyersina | Sibifil | Sifilden | Torfin | Welgra</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Actigra | Avigra | Dynafil | Eraflex | Maklitio | Penimax | Raviag | Revatio | Sildavee | Sildenafil cipla | Sildojub | Silrexia | Silwin | Viagra | Videna | Vigro | Vitrixa</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">7 hours | Aphrodil | Canova | Comit | Cupid | Dr.x | Kamagra | Kifaru | Manforce | Njoi | Perfopil 50 | Seregra | Silagra | Silmet | Ulti-mate | Viagra | Viengray | Virecta | Wingora | Zwagra</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Androz | Avigra | Giagra | Kamagra | Seregra | Viagra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26534956">
<a name="26534956"></a>Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. <i>Circulation</i>. 2015;132(21):2037-2099. doi:10.1161/CIR.0000000000000329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26534956/pubmed" id="26534956" target="_blank">26534956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27034561">
<a name="27034561"></a>Adiga A, Edriss H, Nugent K. Intracranial aneurysm and sildenafil. <i>Proc (Bayl Univ Med Cent)</i>. 2016;29(2):178-180. doi:10.1080/08998280.2016.11929407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27034561/pubmed" id="27034561" target="_blank">27034561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19949232">
<a name="19949232"></a>Ahsman MJ, Witjes BC, Wildschut ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2010;95(2):F109-F114. doi:10.1136/adc.2009.168336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19949232/pubmed" id="19949232" target="_blank">19949232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27589542">
<a name="27589542"></a>Al Omar S, Salama H, Al Hail M, et al. Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. <i>J Neonatal Perinatal Med</i>. 2016;9(3):251-259. doi:10.3233/NPM-16161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27589542/pubmed" id="27589542" target="_blank">27589542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249585">
<a name="25249585"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2014;130(25):e433-e434]. <i>Circulation</i>. 2014;130(25):e344-e426. doi:10.1161/CIR.0000000000000134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/25249585/pubmed" id="25249585" target="_blank">25249585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667180">
<a name="29667180"></a>Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. <i>Br J Pharmacol</i>. 2018;175(13):2554-2565. doi:10.1111/bph.14205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/29667180/pubmed" id="29667180" target="_blank">29667180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28281457">
<a name="28281457"></a>Andrigueti FV, Ebbing PCC, Arismendi MI, Kayser C. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. <i>Clin Exp Rheumatol</i>. 2017;35(suppl 106)(4):151-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/28281457/pubmed" id="28281457" target="_blank">28281457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10422958">
<a name="10422958"></a>Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. <i>Anesthesiology</i>. 1999;91(1):307-310. doi:10.1097/00000542-199907000-00041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/10422958/pubmed" id="10422958" target="_blank">10422958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33809319">
<a name="33809319"></a>Ausó E, Gómez-Vicente V, Esquiva G. Visual side effects linked to sildenafil consumption: An update. <i>Biomedicines</i>. 2021;9(3):291. doi:10.3390/biomedicines9030291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/33809319/pubmed" id="33809319" target="_blank">33809319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16585301">
<a name="16585301"></a>Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. <i>Pediatrics</i>. 2006;117(4):1077-1083. doi:10.1542/peds.2005-0523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16585301/pubmed" id="16585301" target="_blank">16585301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22128226">
<a name="22128226"></a>Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. <i>Circulation</i>. 2012;125(2):324-334. doi:10.1161/CIRCULATIONAHA.110.016667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/22128226/pubmed" id="22128226" target="_blank">22128226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24637559">
<a name="24637559"></a>Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. <i>Circulation</i>. 2014;129(19):1914-1923. doi:10.1161/CIRCULATIONAHA.113.005698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24637559/pubmed" id="24637559" target="_blank">24637559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bednarz.2019">
<a name="Bednarz.2019"></a>Bednarz AM, Israel EN, Beckman EJ, Johansen M, Thomas CA. Safety of enteral sildenafil in hemodynamically unstable children. <i>Cardiology in the Young</i>. 2019;29(5):589-593. doi:10.1017/S1047951119000209</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24680796">
<a name="24680796"></a>Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. <i>Am J Med</i>. 2014;127(7):664-668. doi:10.1016/j.amjmed.2014.03.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24680796/pubmed" id="24680796" target="_blank">24680796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25358826">
<a name="25358826"></a>Campbell UB, Walker AM, Gaffney M, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. <i>J Sex Med</i>. 2015;12(1):139-151. doi:10.1111/jsm.12726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/25358826/pubmed" id="25358826" target="_blank">25358826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512419">
<a name="27512419"></a>Cartago RS, Alan PA, Benedicto J. Pregnancy outcomes in patients with severe pulmonary hypertension and Eisenmenger syndrome treated with sildenafil monotherapy. <i>Obstet Med</i>. 2014;7(1):40-42. doi:10.1177/1753495X13514403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27512419/pubmed" id="27512419" target="_blank">27512419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11176477">
<a name="11176477"></a>Chen J, Mabjeesh NJ, Greenstein A, Nadu A, Matzkin H. Clinical efficacy of sildenafil in patients on chronic dialysis. <i>J Urol</i>. 2001;165(3):819-821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11176477/pubmed" id="11176477" target="_blank">11176477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35624452">
<a name="35624452"></a>Chetan C, Suryawanshi P, Patnaik S, et al. Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial. <i>BMC Pediatr</i>. 2022;22(1):311. doi:10.1186/s12887-022-03366-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/35624452/pubmed" id="35624452" target="_blank">35624452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31740991">
<a name="31740991"></a>Cochius-den Otter SCM, Kipfmueller F, de Winter BCM, et al. Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia. <i>Eur J Clin Pharmacol</i>. 2020;76(2):219-227. doi:10.1007/s00228-019-02767-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/31740991/pubmed" id="31740991" target="_blank">31740991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30396684">
<a name="30396684"></a>Cohen JL, Nees SN, Valencia GA, Rosenzweig EB, Krishnan US. Sildenafil use in children with pulmonary hypertension. <i>J Pediatr</i>. 2019;205:29-34.e1. doi:10.1016/j.jpeds.2018.09.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30396684/pubmed" id="30396684" target="_blank">30396684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27340796">
<a name="27340796"></a>Darland LK, Dinh KL, Kim S, et al. Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. <i>Pediatr Pulmonol</i>. 2017;52(2):232-237. doi:10.1002/ppul.23503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27340796/pubmed" id="27340796" target="_blank">27340796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27926905">
<a name="27926905"></a>Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. <i>Fetal Diagn Ther</i>. 2017;41(2):81-88. doi:10.1159/000453062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27926905/pubmed" id="27926905" target="_blank">27926905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26767411">
<a name="26767411"></a>Dunn L, Flenady V, Kumar S. Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial. <i>J Transl Med</i>. 2016;14:15. doi:10.1186/s12967-016-0769-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26767411/pubmed" id="26767411" target="_blank">26767411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32856285">
<a name="32856285"></a>El-Ghandour M, Hammad B, Ghanem M, Antonios MAM. Efficacy of milrinone plus sildenafil in the treatment of neonates with persistent pulmonary hypertension in resource-limited settings: results of a randomized, double-blind trial. <i>Paediatr Drugs</i>. 2020;22(6):685-693. doi:10.1007/s40272-020-00412-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/32856285/pubmed" id="32856285" target="_blank">32856285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27877095">
<a name="27877095"></a>Fender RA, Hasselman TE, Wang Y, Harthan AA. Evaluation of the tolerability of intermittent intravenous sildenafil in pediatric patients with pulmonary hypertension. <i>J Pediatr Pharmacol Ther</i>. 2016;21(5):419-425. doi:10.5863/1551-6776-21.5.419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27877095/pubmed" id="27877095" target="_blank">27877095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21069290">
<a name="21069290"></a>Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. <i>Intensive Care Med</i>. 2011;37(3):502-509. doi:10.1007/s00134-010-2065-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21069290/pubmed" id="21069290" target="_blank">21069290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16275885">
<a name="16275885"></a>Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. <i>Circulation</i>. 2005;112(19):2980-2985. doi:10.1161/CIRCULATIONAHA.104.523324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16275885/pubmed" id="16275885" target="_blank">16275885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291984">
<a name="16291984"></a>Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension [published correction appears in <i>N Engl J Med</i>. 2006;354(22):2400-2401]. <i>N Engl J Med</i>. 2005;353(20):2148-2157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16291984/pubmed" id="16291984" target="_blank">16291984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25657022">
<a name="25657022"></a>Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. <i>Eur Respir J</i>. 2015;45(5):1314-1322. doi:10.1183/09031936.00105914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/25657022/pubmed" id="25657022" target="_blank">25657022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gallagher.1">
<a name="Gallagher.1"></a>Gallagher SA, Hackett P. High altitude pulmonary edema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.<a href="http://www.uptodate.com" target="_blank"> http://www.uptodate.com</a>. Accessed October 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21072154">
<a name="21072154"></a>Ghafari A, Farshid B, Afshari AT, et al. Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients. <i>Indian J Nephrol</i>. 2010;20(3):142-145. doi:10.4103/0971-4065.70845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21072154/pubmed" id="21072154" target="_blank">21072154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18367027">
<a name="18367027"></a>Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in essential hypertension. <i>Curr Hypertens Rep</i>. 2008;10(1):52-57. doi:10.1007/s11906-008-0011-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18367027/pubmed" id="18367027" target="_blank">18367027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900167">
<a name="19900167"></a>Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. <i>Int J Clin Pract</i>. 2010;64(2):240-255. doi:10.1111/j.1742-1241.2009.02254.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19900167/pubmed" id="19900167" target="_blank">19900167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30079989">
<a name="30079989"></a>Groom KM, Ganzevoort W, Alfirevic Z, Lim K, Papageorghiou AT; STRIDER Consortium. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. <i>Ultrasound Obstet Gynecol</i>. 2018;52(3):295-296. doi:10.1002/uog.19186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30079989/pubmed" id="30079989" target="_blank">30079989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30779295">
<a name="30779295"></a>Groom KM, McCowan LM, Mackay LK, et al. STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. <i>BJOG</i>. 2019;126(8):997-1006. doi:10.1111/1471-0528.15658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30779295/pubmed" id="30779295" target="_blank">30779295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15200445">
<a name="15200445"></a>Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. <i>Kidney Int</i>. 2004;66(1):367-374. doi:10.1111/j.1523-1755.2004.00739.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/15200445/pubmed" id="15200445" target="_blank">15200445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17409761">
<a name="17409761"></a>Hayat S, Al-Mutairy M, Zubaid M, Suresh C. Acute myocardial infarction following sildenafil intake in a nitrate-free patient without previous history of coronary artery disease. <i>Med Princ Pract</i>. 2007;16(3):234-236. doi:10.1159/000100397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/17409761/pubmed" id="17409761" target="_blank">17409761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21736676">
<a name="21736676"></a>Hsu CH, Gomberg-Maitland M, Glassner C, et al. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. <i>Int J Clin Pract Suppl.</i> 2011;172:6-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21736676/pubmed" id="21736676" target="_blank">21736676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J.</i> 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21138617">
<a name="21138617"></a>Humpl T, Reyes JT, Erickson S, et al. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. <i>Cardiol Young. </i>2011;21(2):187-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21138617/pubmed" id="21138617" target="_blank">21138617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29331003">
<a name="29331003"></a>Hussain AS, Ali R, Ahmed S, Naz F, Haroon A. Oral sildenafil use in neonates with persistent pulmonary hypertension of newborn. <i>J Ayub Med Coll Abbottabad</i>. 2017;29(4):677-680.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/29331003/pubmed" id="29331003" target="_blank">29331003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35350163">
<a name="35350163"></a>Hussain WA, Bondi DS, Shah P, Morgan SE, Sriram S, Schreiber MD. Implementation of an inhaled nitric oxide weaning protocol and stewardship in a level 4 NICU to decrease inappropriate use. <i>J Pediatr Pharmacol Ther</i>. 2022;27(3):284-291. doi:10.5863/1551-6776-27.3.284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/35350163/pubmed" id="35350163" target="_blank">35350163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11587397">
<a name="11587397"></a>Juergense PH, Botev R, Wuerth D, Finkelstein SH, Smith JD, Finkelstein FO. Erectile dysfunction in chronic peritoneal dialysis patients: incidence and treatment with sildenafil. <i>Perit Dial Int</i>. 2001;21(4):355-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11587397/pubmed" id="11587397" target="_blank">11587397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33980104">
<a name="33980104"></a>Kamran A, Rafiq N, Khalid A, et al. Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital. <i>J Matern Fetal Neonatal Med</i>. 2022;35(25):6787-6793. doi:10.1080/14767058.2021.1923003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/33980104/pubmed" id="33980104" target="_blank">33980104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21520123">
<a name="21520123"></a>Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E. Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors. <i>Laryngoscope</i>. 2011;121(5):1049-1054. doi:10.1002/lary.21450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21520123/pubmed" id="21520123" target="_blank">21520123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32117027">
<a name="32117027"></a>Karaarslan C. Ocular side effects of sildenafil that persist beyond 24 h-A case series. <i>Front Neurol</i>. 2020;11:67. doi:10.3389/fneur.2020.00067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/32117027/pubmed" id="32117027" target="_blank">32117027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khera.1">
<a name="Khera.1"></a>Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.<a href="http://www.uptodate.com" target="_blank"> http://www.uptodate.com</a>. Accessed February 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15533876">
<a name="15533876"></a>Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i>. 2004;110(19):3149-3155. doi:10.1161/01.CIR.0000146906.42375.D3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/15533876/pubmed" id="15533876" target="_blank">15533876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16387566">
<a name="16387566"></a>Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. <i>Am J Cardiol</i>. 2005;96(12B):42M-46M. doi:10.1016/j.amjcard.2005.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16387566/pubmed" id="16387566" target="_blank">16387566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28645441">
<a name="28645441"></a>Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. <i>J Pediatr</i>. 2017;188:24-34.e1. doi:10.1016/j.jpeds.2017.05.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/28645441/pubmed" id="28645441" target="_blank">28645441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18701525">
<a name="18701525"></a>Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. <i>J Intensive Care Med</i>. 2008;23(5):329-334. doi:10.1177/0885066608321389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18701525/pubmed" id="18701525" target="_blank">18701525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32235216">
<a name="32235216"></a>Lee Y, Park KA, Oh SY, Min JH, Kim BJ. Fourth cranial nerve palsy associated with sildenafil citrate. <i>J Neuroophthalmol</i>. 2021;41(1):e79-e80. doi:10.1097/WNO.0000000000000938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/32235216/pubmed" id="32235216" target="_blank">32235216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30773787">
<a name="30773787"></a>Levin G, Rottenstreich A. Sildenafil citrate in obstetrics - caution is advised. <i>BJOG</i>. 2019;126(6):736. doi:10.1111/1471-0528.15605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30773787/pubmed" id="30773787" target="_blank">30773787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24710960">
<a name="24710960"></a>Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. <i>JAMA Intern Med</i>. 2014;174(6):964-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24710960/pubmed" id="24710960" target="_blank">24710960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31074218">
<a name="31074218"></a>Lim K, Chang SA, Oh SY, et al. Pulmonary arterial hypertension and pregnancy: single center experience in current era of targeted therapy. <i>Korean Circ J</i>. 2019;49(6):545-554. doi:10.4070/kcj.2018.0350<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/31074218/pubmed" id="31074218" target="_blank">31074218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Liqrev.1">
<a name="Liqrev.1"></a>Liqrev (sildenafil) [prescribing information]. Farmville, NC: CMP Pharma Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29884471">
<a name="29884471"></a>Liu B, Zhu L, Zhong J, Zeng G, Deng T. The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: A systematic review and meta-analysis. <i>Sex Med</i>. 2018;6(3):185-192. doi:10.1016/j.esxm.2018.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/29884471/pubmed" id="29884471" target="_blank">29884471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26103029">
<a name="26103029"></a>Loeb S, Folkvaljon Y, Lambe M, et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. <i>JAMA</i>. 2015;313(24):2449-2455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26103029/pubmed" id="26103029" target="_blank">26103029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22023666">
<a name="22023666"></a>Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. <i>J Sex Med</i>. 2012;9(1):265-270. doi:10.1111/j.1743-6109.2011.02537.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/22023666/pubmed" id="22023666" target="_blank">22023666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31248818">
<a name="31248818"></a>Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. <i>Wilderness Environ Med</i>. 2019;30(4S):S3-S18. doi:10.1016/j.wem.2019.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/31248818/pubmed" id="31248818" target="_blank">31248818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21527519">
<a name="21527519"></a>Machado RF, Barst RJ, Yovetich NA, et al; walk-PHaSST Investigators and Patients. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. <i>Blood</i>. 2011;118(4):855-864. doi:10.1182/blood-2010-09-306167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21527519/pubmed" id="21527519" target="_blank">21527519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19507217">
<a name="19507217"></a>Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. <i>Laryngoscope</i>. 2009;119(8):1586-1589. doi:10.1002/lary.20511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19507217/pubmed" id="19507217" target="_blank">19507217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30122565">
<a name="30122565"></a>Maged M, Wageh A, Shams M, Elmetwally A. Use of sildenafil citrate in cases of intrauterine growth restriction (IUGR); a prospective trial. <i>Taiwan J Obstet Gynecol</i>. 2018;57(4):483-486. doi:10.1016/j.tjog.2018.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30122565/pubmed" id="30122565" target="_blank">30122565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30315625">
<a name="30315625"></a>Maher MA, Sayyed TM, El-Khadry SW. Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labour: a randomised trial. <i>BJOG</i>. 2019;126(6):729-735. doi:10.1111/1471-0528.15503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30315625/pubmed" id="30315625" target="_blank">30315625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36249994">
<a name="36249994"></a>Mahmoud A, Abid F, Khairallah M, et al. Case report: central retinal artery occlusion following sildenafil intake. <i>F1000Res</i>. 2022;11:600. doi:10.12688/f1000research.122087.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/36249994/pubmed" id="36249994" target="_blank">36249994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15685517">
<a name="15685517"></a>Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. <i>Am J Kidney Dis</i>. 2005;45(2):381-387. doi:10.1053/j.ajkd.2004.10.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/15685517/pubmed" id="15685517" target="_blank">15685517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20479381">
<a name="20479381"></a>McGwin G Jr. Phosphodiesterase type 5 inhibitor use and hearing impairment. <i>Arch Otolaryngol Head Neck Surg</i>. 2010;136(5):488-492. doi:10.1001/archoto.2010.51<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/20479381/pubmed" id="20479381" target="_blank">20479381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol.</i> 2009;53(17):1573-1619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11706126">
<a name="11706126"></a>Morgan JC, Alhatou M, Oberlies J, Johnston KC. Transient ischemic attack and stroke associated with sildenafil (Viagra) use. <i>Neurology</i>. 2001;57(9):1730-1731. doi:10.1212/wnl.57.9.1730<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11706126/pubmed" id="11706126" target="_blank">11706126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27799745">
<a name="27799745"></a>Moschos MM, Nitoda E. Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. <i>Drug Des Devel Ther</i>. 2016;8:3407-3413. doi:10.2147/DDDT.S118015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27799745/pubmed" id="27799745" target="_blank">27799745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18950791">
<a name="18950791"></a>Mourani PM, Sontag MK, Ivy DD, et al. Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants With Chronic Lung Disease. <i>J Pediatr.</i> 2009;154(3):379-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18950791/pubmed" id="18950791" target="_blank">18950791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11879256">
<a name="11879256"></a>Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. <i>Br J Clin Pharmacol</i>. 2002;53(suppl 1):21S-30S. doi:10.1046/j.0306-5251.2001.00029.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11879256/pubmed" id="11879256" target="_blank">11879256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18800037">
<a name="18800037"></a>Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: Evidence of rapid maturation of metabolic clearance in the early postnatal period. <i>Clin Pharmacol Ther.</i> 2009;85(1):56-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18800037/pubmed" id="18800037" target="_blank">18800037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16917115">
<a name="16917115"></a>Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. <i>Am J Respir Crit Care Med</i>. 2006;174(9):1042-1047. doi:10.1164/rccm.200605-694OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16917115/pubmed" id="16917115" target="_blank">16917115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25295683">
<a name="25295683"></a>Nathoo NA, Etminan M, Mikelberg FS. Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. <i>J Neuroophthalmol</i>. 2015;35(1):12-15. doi:10.1097/WNO.0000000000000186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/25295683/pubmed" id="25295683" target="_blank">25295683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20206543">
<a name="20206543"></a>Nemoto S, Sasaki T, Ozawa H, et al. Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children. <i>Eur J Cardiothorac Surg</i>. 2010;38(1):71-77. doi:10.1016/j.ejcts.2010.01.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/20206543/pubmed" id="20206543" target="_blank">20206543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34228973">
<a name="34228973"></a>Novick WM, Golovenko OS, Lazorhyshynets VV, Dedovich VV, DiSessa TG. Sildenafil's early, late impact on ventricular septal repair: older children using the double patch. <i>Ann Thorac Surg</i>. 2022;114(3):818-825. doi:10.1016/j.athoracsur.2021.06.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/34228973/pubmed" id="34228973" target="_blank">34228973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19134242">
<a name="19134242"></a>Okuyucu S, Guven OE, Akoglu E, Uçar E, Dagli S. Effect of phosphodiesterase-5 inhibitor on hearing. <i>J Laryngol Otol</i>. 2009;123(7):718-722. doi:10.1017/S002221510900423X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19134242/pubmed" id="19134242" target="_blank">19134242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21720460">
<a name="21720460"></a>Palma G, Giordano R, Russolillo V, et al. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. <i>Tex Heart Inst J.</i> 2011;38(3):238-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21720460/pubmed" id="21720460" target="_blank">21720460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36046329">
<a name="36046329"></a>Pawar T, Saboo K, Patel M, Kumar S, Acharya S. Sildenafil-induced acute fulminant hepatic failure: tragedy after triumph. <i>Cureus</i>. 2022;14(7):e27378. doi:10.7759/cureus.27378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/36046329/pubmed" id="36046329" target="_blank">36046329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29282009">
<a name="29282009"></a>Pels A, Kenny LC, Alfirevic Z, et al; international STRIDER Consortium. STRIDER (Sildenafil Therapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):440. doi:10.1186/s12884-017-1594-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/29282009/pubmed" id="29282009" target="_blank">29282009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34052232">
<a name="34052232"></a>Pierce CM, Zhang MH, Jonsson B, et al. Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): a multicenter, randomized, placebo-controlled trial. <i>J Pediatr</i>. 2021;237:154-161.e3. doi:10.1016/j.jpeds.2021.05.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/34052232/pubmed" id="34052232" target="_blank">34052232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30345157">
<a name="30345157"></a>Qasim A, Dasgupta S, Aly AM, Jain SK. Sildenafil use in the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension: a case series. <i>AJP Rep</i>. 2018;8(4):e219-e222. doi:10.1055/s-0038-1673343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30345157/pubmed" id="30345157" target="_blank">30345157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34761138">
<a name="34761138"></a>Regenold J, Ghoraba H, Akhavanrezayat A, et al. Unilateral acute anterior uveitis with macular edema following the use of sildenafil citrate in a patient with HLA-B27 positivity. <i>Am J Ophthalmol Case Rep</i>. 2021;24:101228. doi:10.1016/j.ajoc.2021.101228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/34761138/pubmed" id="34761138" target="_blank">34761138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Revatio.2020.02">
<a name="Revatio.2020.02"></a>Revatio (sildenafil citrate) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Revatio.2021.02">
<a name="Revatio.2021.02"></a>Revatio (sildenafil citrate) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32622767">
<a name="32622767"></a>Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors? <i>J Sex Med</i>. 2020;17(8):1579-1582. doi:10.1016/j.jsxm.2020.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/32622767/pubmed" id="32622767" target="_blank">32622767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35513541">
<a name="35513541"></a>Rhee SJ, Shin SH, Oh J, et al. Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension. <i>Sci Rep</i>. 2022;12(1):7393. doi:10.1038/s41598-022-11038-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/35513541/pubmed" id="35513541" target="_blank">35513541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11136178">
<a name="11136178"></a>Rosas SE, Wasserstein A, Kobrin S, Feldman HI. Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. <i>Am J Kidney Dis</i>. 2001;37(1):134-137. doi:10.1053/ajkd.2001.20608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11136178/pubmed" id="11136178" target="_blank">11136178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23426043">
<a name="23426043"></a>Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomized trials. <i>Ann Rheum Dis</i>. 2013;72(10):1696-1699. doi:10.1136/annrheumdis-2012-202836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23426043/pubmed" id="23426043" target="_blank">23426043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30383134">
<a name="30383134"></a>Roustit M, Giai J, Gaget O, et al. On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials. <i>Ann Intern Med</i>. 2018;169(10):694-703. doi:10.7326/M18-0517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30383134/pubmed" id="30383134" target="_blank">30383134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21546436">
<a name="21546436"></a>Rubin LJ, Badesch DB, Fleming TR, et al; SUPER-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. <i>Chest</i>. 2011;140(5):1274-1283. doi:10.1378/chest.10-0969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21546436/pubmed" id="21546436" target="_blank">21546436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30194048">
<a name="30194048"></a>Russo FM, Conings S, Allegaert K, et al. Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model. <i>Am J Obstet Gynecol</i>. 2018;219(6):619.e1-619.e10. doi:10.1016/j.ajog.2018.08.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30194048/pubmed" id="30194048" target="_blank">30194048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sauer.1">
<a name="Sauer.1"></a>Sauer WH, Kimmel SE. Sexual activity in patients with cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.<a href="http://www.uptodate.com" target="_blank"> http://www.uptodate.com</a>. Accessed September 23, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12397048">
<a name="12397048"></a>Seibel I, Poli De Figueiredo CE, Telöken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. <i>J Am Soc Nephrol</i>. 2002;13(11):2770-2775. doi:10.1097/01.asn.0000034201.97937.3e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/12397048/pubmed" id="12397048" target="_blank">12397048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35337380">
<a name="35337380"></a>Shalbafan M, Orooji M, Kamalzadeh L. Psychosis beas a rare side effect of sildenafil: a case report. <i>J Med Case Rep</i>. 2022;16(1):120. doi:10.1186/s13256-022-03334-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/35337380/pubmed" id="35337380" target="_blank">35337380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26440237">
<a name="26440237"></a>Sharma VK, Joshi S, Joshi A, Kumar G, Arora H, Garg A. Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children? - a prospective randomized study. <i>Ann Card Anaesth</i>. 2015;18(4):510-516. doi:10.4103/0971-9784.166457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26440237/pubmed" id="26440237" target="_blank">26440237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34143564">
<a name="34143564"></a>Sharma C, Burns J, Kulkarni A, Cerise JE, Molina Berganza F, Hayes DA. Continuous and intermittent administration of intravenous sildenafil in critically ill infants with pulmonary hypertension. <i>Pediatr Pulmonol</i>. 2021;56(9):2973-2978. doi:10.1002/ppul.25539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/34143564/pubmed" id="34143564" target="_blank">34143564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30169244">
<a name="30169244"></a>Sharp A, Cornforth C, Jackson R, et al; STRIDER group. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial [published correction appears in <i>Lancet Child Adolesc Health</i>. 2018;2(2):e2]. <i>Lancet Child Adolesc Health</i>. 2018;2(2):93-102. doi:10.1016/S2352-4642(17)30173-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/30169244/pubmed" id="30169244" target="_blank">30169244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19836028">
<a name="19836028"></a>Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. <i>J Pediatr.</i> 2009;155(6):841-847.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19836028/pubmed" id="19836028" target="_blank">19836028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23413163">
<a name="23413163"></a>Stultz JS, Puthoff T, Backes C Jr, Nahata MC. Intermittent intravenous sildenafil for pulmonary hypertension management in neonates and infants. <i>Am J Health Syst Pharm</i>. 2013;70(5):407-413. doi:10.2146/ajhp120364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23413163/pubmed" id="23413163" target="_blank">23413163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24937180">
<a name="24937180"></a>Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi:10.1378/chest.14-0793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24937180/pubmed" id="24937180" target="_blank">24937180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25796626">
<a name="25796626"></a>Tan K, Krishnamurthy MB, O'Heney JL, Paul E, Sehgal A. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety. <i>Eur J Pediatr</i>. 2015;174(8):1109-1115. doi:10.1007/s00431-015-2515-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/25796626/pubmed" id="25796626" target="_blank">25796626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25824807">
<a name="25824807"></a>Trottier-Boucher MN, Lapointe A, Malo J, et al. Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. <i>Pediatr Cardiol</i>. 2015;36(6):1255-1260. doi:10.1007/s00246-015-1154-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/25824807/pubmed" id="25824807" target="_blank">25824807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11522864">
<a name="11522864"></a>Türk S, Karalezli G, Tonbul HZ, et al. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. <i>Nephrol Dial Transplant</i>. 2001;16(9):1818-1822. doi:10.1093/ndt/16.9.1818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11522864/pubmed" id="11522864" target="_blank">11522864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20054528">
<a name="20054528"></a>Uhm JY, Jhang WK, Park JJ, et al. Postoperative use of oral sildenafil in pediatric patients with congenital heart disease. <i>Pediatr Cardiol.</i> 2010;31(4):515-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/20054528/pubmed" id="20054528" target="_blank">20054528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21219411">
<a name="21219411"></a>Vachiery JL, Huez S, Gillies H, et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. <i>Br J Clin Pharmacol</i>. 2011;71(2):289-292. doi:10.1111/j.1365-2125.2010.03831.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21219411/pubmed" id="21219411" target="_blank">21219411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19866403">
<a name="19866403"></a>Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcón-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. <i>Am J Perinatol</i>. 2010;27(3):225-230. doi:10.1055/s-0029-1239496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19866403/pubmed" id="19866403" target="_blank">19866403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21457152">
<a name="21457152"></a>Vassalos A, Peng E, Young D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: A randomised trial in children undergoing cardiac surgery. <i>Anaesthesia. </i>2011;66(6):472-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21457152/pubmed" id="21457152" target="_blank">21457152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Viagra.2017.12">
<a name="Viagra.2017.12"></a>Viagra (sildenafil citrate) [prescribing information]. New York, NY: Pfizer Labs; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Viagra.2020.05">
<a name="Viagra.2020.05"></a>Viagra (sildenafil citrate) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wigley.1">
<a name="Wigley.1"></a>Wigley FM. Treatment of Raynaud phenomenon: Initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.<a href="http://www.uptodate.com" target="_blank"> http://www.uptodate.com</a>. Accessed January 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26717019">
<a name="26717019"></a>Wollein U, Schech B, Hardt J, Schramek N. Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman. <i>J Pharm Biomed Anal</i>. 2016;120:100-105. doi:10.1016/j.jpba.2015.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26717019/pubmed" id="26717019" target="_blank">26717019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923561">
<a name="28923561"></a>Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. <i>Sex Med Rev</i>. 2018;6(2):242-252. doi:10.1016/j.sxmr.2017.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/28923561/pubmed" id="28923561" target="_blank">28923561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12175405">
<a name="12175405"></a>YeniçerioGlu Y, Kefi A, Aslan G, et al. Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. <i>BJU Int</i>. 2002;90(4):442-445. doi:10.1046/j.1464-410x.2002.02914.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/12175405/pubmed" id="12175405" target="_blank">12175405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10078541">
<a name="10078541"></a>Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. <i>Am J Cardiol</i>. 1999;83(5A):35C-44C. doi:10.1016/s0002-9149(99)00046-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/10078541/pubmed" id="10078541" target="_blank">10078541</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9643 Version 665.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
